Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46.2M
-
Number of holders
-
29
-
Total 13F shares, excl. options
-
3.12M
-
Shares change
-
-144K
-
Total reported value, excl. options
-
$98.4M
-
Value change
-
+$1.69M
-
Number of buys
-
18
-
Number of sells
-
-9
-
Price
-
$31.52
Significant Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q3 2017
33 filings reported holding URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share as of Q3 2017.
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) has 29 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.12M shares
of 46.2M outstanding shares and own 6.75% of the company stock.
Largest 10 shareholders include FMR LLC (769K shares), MENORA MIVTACHIM HOLDINGS LTD. (570K shares), HIGHLINE CAPITAL MANAGEMENT, L.P. (410K shares), WELLINGTON MANAGEMENT GROUP LLP (289K shares), PERCEPTIVE ADVISORS LLC (269K shares), JENNISON ASSOCIATES LLC (149K shares), Wildcat Capital Management, LLC (135K shares), CREDIT SUISSE AG/ (100K shares), DSAM Partners (London) Ltd (74.5K shares), and BAINCO INTERNATIONAL INVESTORS (72.5K shares).
This table shows the top 29 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.